|
|
Volumn 94, Issue 12, 2002, Pages 874-875
|
|
Breaking the silence: The rise of epigenetic therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID;
5 AZA 2' DEOXYCYTIDINE;
DEPSIPEPTIDE;
FK 288;
HISTONE DEACETYLASE INHIBITOR;
METHYLTRANSFERASE INHIBITOR;
MG 98;
N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE;
UNCLASSIFIED DRUG;
VORINOSTAT;
ANTINEOPLASTIC ACTIVITY;
BLADDER CANCER;
CANCER GENETICS;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DNA METHYLATION;
DRUG EFFECT;
DRUG MARKETING;
DRUG MECHANISM;
DRUG POTENCY;
DRUG RESPONSE;
DRUG SAFETY;
HUMAN;
LEUKEMIA;
LUNG CANCER;
NOTE;
PRIORITY JOURNAL;
T CELL LYMPHOMA;
|
|
EID: 0037134696
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.12.874 Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|